

## Toxins and the Immune System in PANS and PANDAS Lecture References

Scott Antoine, DO, FACEP, ABOIM

**Note:** These 86 references are extracted from over 1200 found in:

*The Comprehensive Physicians' Guide to the management of PANS and PANDAS, An Evidence-based Approach to Diagnosis, Testing, and Effective Treatment* © 2023, Dr. Scott Antoine, all rights reserved

Available to order here: <https://a.co/d/gOtsUVC>

1. Belkaid Y, Hand TW: Role of the microbiota in immunity and inflammation. *Cell*. 2014;157:121-141
2. Mathis D, Benoist C: Microbiota and autoimmune disease: the hosted self. *Cell Host Microbes*. 2011;10:297-301
3. Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. *Acta Paediatr*. 2005;94(4):386-93
4. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes*. 2012;3(1):4-14
5. Rees JC. Obsessive-compulsive disorder and gut microbiota dysregulation. *Med Hypotheses*. 2014;82(2):163-6
6. Chen B, Sun L, Zhang X. Integration of microbiome and epigenome to decipher the pathogenesis of autoimmune diseases. *J Autoimmun*. 2017;83:31-42
7. <https://www.health.harvard.edu/blog/leaky-gut-what-is-it-and-what-does-it-mean-for-you-2017092212451>, accessed 10/20/2021
8. Picco P, Gattorno M, Marchese N, et al. Increased gut permeability in juvenile chronic arthritides. A multivariate analysis of the diagnostic parameters. *Clin Exp Rheumatol*. 2000;18(6):773-8
9. Behar SM, Porcelli S: Mechanisms of autoimmune disease induction. *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology*. 1995;38(4):58-476
10. Porcelli S: Molecular mimicry and the generation of autoimmune diseases. *Rheumatol Rev*. 1993;2:41-50
11. Damian RT: Molecular mimicry: antigen sharing by parasite and host and its consequences. *Am Naturalist*. 1964;98: 129-149
12. Bryant PA, Smyth GK, Gooding T, et al. Susceptibility to acute rheumatic fever based on differential expression of genes involved in cytotoxicity, chemotaxis, and apoptosis. *Infect Immun*. 2014;82:753–761

13. Guilherme L, Kalil J, Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. *Autoimmunity*. 2006;39(1):31-9
14. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW: Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. *Nat Med*. 2003;9(7):914
15. Church AJ, Cardoso F, Dale RC, Lees AJ, Thompson EJ, Giovannoni G: Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. *Neurology*. 2002;59(2):227
16. Guyatt G. Evidence-based Medicine. *ACP Journal Club*. 1991;14(Supp 2):A-16
17. Evidence-based Medicine Working Group. Evidence-based Medicine. A new approach to teaching the practice of medicine. *JAMA*. 1992;268(17):2420-2425
18. Sackett DL, Rosenberg WMC, Gray JAM, et al. Evidence based medicine: what it is and what it isn't. *BMJ*. 1996;312:71
19. Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice. *ACP J Club*. 2002;136(2):A11-4
20. Riedel M, Straube A, Schwarz MJ, et al. Lyme disease presenting as Tourette's syndrome. *The Lancet*. 1998;351(9100):418-9
21. Alaedini A, Latov N. Antibodies against OspA epitopes of *Borrelia burgdorferi* cross-react with neural tissue. *J Neuroimmunol*. 2005;159(1-2):192-5
22. Gleichmann E, Kimber I, Purchase IFH. Immunotoxicology: suppressive and stimulatory effects of drugs and environmental chemicals on the immune system. *Archives of toxicology*. 1989;63(4):257-273
23. Mokarizadeh A, et al. A comprehensive review of pesticides and the immune dysregulation: mechanisms, evidence and consequences. *Toxicology mechanisms and methods*. 2015;25(4):258-278
24. Peillex C, Pelletier M. The impact and toxicity of glyphosate and glyphosate-based herbicides on health and immunity. *Journal of Immunotoxicology*. 2020;17(1):163-174
25. Bouchard MF, Bellinger DC, Weuve J, et al. Blood lead levels and major depressive disorder, panic disorder, and generalized anxiety disorder in US young adults. *Arch Gen Psychiatry*. 2009;66(12):1313-1319
26. Gump BB, Dykas MJ, MacKenzie JA, et al. Background lead and mercury exposures: Psychological and behavioral problems in children. *Environ Res*. 2017;158:576-582
27. Mishra KP: Lead exposure and its impact on immune system: a review. *Toxicol In Vitro*. 2009;23(6):969-72
28. Lutz PM, Wilson TJ, Ireland J, et al. Elevated immunoglobulin E (IgE) levels in children with exposure to environmental lead. *Toxicology*. 1999;134:63-78
29. McCabe MJ, Lawrence DA. Lead, a major environmental pollutant, is immunomodulatory by its differential effects on CD4+ T cell subsets. *Toxicology and Applied Pharmacology*. 1991;111:13-23

30. Sun L, Hu J, Zhao Z, et al. Influence of exposure to environmental lead on serum immunoglobulin in preschool children. *Environmental Research*. 2003;92:124-128
31. Lawrence DA, McCabe MJ. Immunomodulation by metals. *International Immunopharmacology*. 2002;2:293-302
32. Bennett JW, Klich M. Mycotoxins. *Clin Microbiol Rev*. 2003;16(3):497-516
33. Ratnaseelan AM, Tsilioni I, Theoharides TC. Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes. *Clin Ther*. 2018;40(6):903-917
34. Gray MR, Thrasher JD, Crago R, et al. Mixed mold mycotoxicosis: immunological changes in humans following exposure in water-damaged buildings. *Arch Environ Health*. 2003;58(7):410-20
35. Al-anati L, and Petzinger E. Immunotoxic activity of ochratoxin A. *Journal of Veterinary Pharmacology and Therapeutics*. 2006;29:79-90
36. Bulgaru CV, Marin DE, Pistol GC, Taranu I: Zearalenone and the Immune Response. *Toxins (Basel)*. 2021;13(4):248
37. Wu Q, Wu W, Franca TCC, et al. Immune Evasion, a Potential Mechanism of Trichothecenes: New Insights into Negative Immune Regulations. *International Journal of Molecular Sciences*. 2018;19(11):3307
38. Wu G, Fang YZ, Yang S, et al. Glutathione metabolism and its implications for health. *J Nutr*. 2004;134(3):489-92
39. Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. *Trends Pharmacol Sci*. 2008;29(7):346-51
40. Chatterjee S. Oxidative stress, inflammation, and disease. In *Oxidative stress and biomaterials*. London, UK. Academic Press. 2016:35-58
41. <https://www.moleculeralabs.com/cunningham-panel-results-sensitivity-specificity/>, accessed 8/1/2023
42. Watson SC, Liu Y, Lund RB, et al. A Bayesian spatio-temporal model for forecasting the prevalence of antibodies to *Borrelia burgdorferi*, causative agent of Lyme disease, in domestic dogs within the contiguous United States. *PLoS ONE*. 2017;12(5): e0174428:1-22
43. Flemming HC, Wingender J. The biofilm matrix. *Nature reviews microbiology*. 2010;8(9):623-33
44. Hong JY, Yang CS. Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. *Environmental health perspectives*. 1997;105(suppl 4):759-62
45. Hodgson E, Rose RL. Human metabolic interactions of environmental chemicals. *J Biochem Mol Toxicol*. 2007;21(4):182-6
46. Schelstraete W, Devreese M, Croubels S. Impact of Subacute Exposure to T-2 Toxin and Zearalenone on the Pharmacokinetics of Midazolam as CYP3A Probe

- Drug in a Porcine Animal Model: A Pilot Study. *Front Pharmacol.* 2019;10:399:1-22
47. Flora K, Hahn M, Rosen H, et al. Milk thistle (*Silybum marianum*) for the therapy of liver disease. *The American journal of gastroenterology.* 1998;93(2):139-43
48. Ketterer B, Coles B, Meyer DJ. The role of glutathione in detoxication. *Environmental Health Perspectives.* 1983;49:59-69
49. Schulz JB, Lindenau J, Seyfried J, et al. Glutathione, oxidative stress and neurodegeneration. *Eur J Biochem.* 2000;267(16):4904-11
50. Guilford FT, Hope J. Deficient glutathione in the pathophysiology of mycotoxin-related illness. *Toxins.* 2014;6(2):608-23
51. Ramos AJ, Fink-Gremmels J, Hernández E. Prevention of Toxic Effects of Mycotoxins by Means of Nonnutritive Adsorbent Compounds. *J Food Prot.* 1996;59(6):631-641
52. Bhatti SA, Khan MZ, Hassan ZU, et al. Comparative efficacy of Bentonite clay, activated charcoal and *Trichosporon mycotoxinivorans* in regulating the feed-to-tissue transfer of mycotoxins. *J Sci Food Agric.* 2018;98(3):884-890
53. Basha MP, Begum S, Mir BA. Neuroprotective Actions of Clinoptilolite and Ethylenediaminetetraacetic Acid Against Lead-induced Toxicity in Mice *Mus musculus.* *Toxicol Int.* 2013;20(3):201-7
54. De Mil T, Devreese M, De Baere S, et al. Characterization of 27 mycotoxin binders and the relation with in vitro zearalenone adsorption at a single concentration. *Toxins (Basel).* 2015;7(1):21-33
55. Haus M, Žatko D, Vašková J, et al. The effect of humic acid in chronic deoxynivalenol intoxication. *Environmental Science and Pollution Research.* 2021;28:1612-8
56. Kabak B, Brandon EF, Var I, et al. Effects of probiotic bacteria on the bioaccessibility of aflatoxin B(1) and ochratoxin A using an in vitro digestion model under fed conditions. *J Environ Sci Health B.* 2009;44(5):472-80
57. Shetty PH, Jespersen L. *Saccharomyces cerevisiae* and lactic acid bacteria as potential mycotoxin decontaminating agents. *Trends in food science & technology.* 2006;17(2):48-55
58. Arif M, Iram A, Bhutta MA, et al. The biodegradation role of *Saccharomyces cerevisiae* against harmful effects of mycotoxin contaminated diets on broiler performance, immunity status, and carcass characteristics. *Animals.* 2020;10(2):238:1-11
59. Li Z, You Y, Griffin N, et al. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. *Int Immunopharmacol.* 2018;61:178-184

60. Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. *Mult Scler*. 2008;14(8):1076-83
61. Mischoulon D, Hylek L, Yeung AS, et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. *J Affect Disord*. 2017;208:6-14
62. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. *Annu Rev Immunol*. 2008;26:513-33
63. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? *Nat Rev Immunol*. 2013;13(3):176-89
64. Del Casale A, Sorice S, Padovano A, et al. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD). *Curr Neuropharmacol*. 2019;17(8):710-736
65. Blier P, Habib R, Flament MF. Pharmacotherapies in the management of obsessive-compulsive disorder. *Canadian Journal of Psychiatry*. 2006;51(7):417-30
66. Murphy TK, Storch EA, Strawser MS: Selective serotonin reuptake inhibitor-induced behavioral activation in the PANDAS subtype. *Primary Psychiatry*. 2006;13:87-89
67. Calaprice D, Tona J. Treatment of pediatric acute-onset neuropsychiatric disorder in a large survey population. *J. Child Adolesc. Psychopharmacol*, 2017;28(2):92-103
68. Abramowitz JS. The psychological treatment of obsessive-compulsive disorder. *Can J Psychiatry*. 2006;51(7):407-16
69. Van Noppen B, Sassano-Higgins S, Appasani R, et al. Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder: 2021 Update. *Focus*. 2021;19(4):430-43
70. Öst LG, Riise EN, Wergeland GJ, et al. Cognitive behavioral and pharmacological treatments of OCD in children: A systematic review and meta-analysis. *J Anxiety Disord*. 2016;43:58-69
71. McGuire JF, Piacentini J, Lewin AB, et al. A Meta-analysis of Cognitive Behavior Therapy and Medication for Child Obsessive-compulsive Disorder: Moderators of Treatment Efficacy, Response, and Remission. *Depress Anxiety*. 2015;32(8):580-93
72. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. *Am J Psychiatry*. 2005;162(1):151-61

73. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. *New England Journal of Medicine*. 2008;359(26):2753-66
74. Wang Z, Whiteside SPH, Sim L, et al. Comparative Effectiveness and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders: A Systematic Review and Meta-analysis. *JAMA Pediatr*. 2017;171(11):1049–1056
75. Piacentini J, Woods DW, Scahill L, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. *JAMA*. 2010;303(19):1929-37
76. Stewart JH. Hypnosis in contemporary medicine. *Mayo Clin Proc*. 2005;80(4):511-24
77. Schulz-Stübner S, Krings T, Meister IG, et al. Clinical hypnosis modulates functional magnetic resonance imaging signal intensities and pain perception in a thermal stimulation paradigm. *Reg Anesth Pain Med*. 2004;29(6):549-56
78. Rainville P, Hofbauer RK, Bushnell MC, et al. Hypnosis modulates activity in brain structures involved in the regulation of consciousness. *Journal of cognitive neuroscience*. 2002;14(6):887-901
79. Saadat H, Kain ZN. Hypnosis as a therapeutic tool in pediatrics. *Pediatrics*. 2007;120(1):179-81
80. Kohen DP, Kaiser P. Clinical Hypnosis with Children and Adolescents-What? Why? How?: Origins, Applications, and Efficacy. *Children (Basel)*. 2014;1(2):74-98
81. Thompson T, Terhune DB, Oram C, et al. The effectiveness of hypnosis for pain relief: A systematic review and meta-analysis of 85 controlled experimental trials. *Neurosci Biobehav Rev*. 2019;99:298-310
82. Culbert TP, Kajander RL, Kohen DP, Reaney JB. Hypnobehavioral approaches for school-age children with dysphagia and food aversion: a case series. *J Dev Behav Pediatr*. 1996;17: 335–341
83. Kohen DP. Hypnotherapeutic management of pediatric and adolescent trichotillomania. *J Dev Behav Pediatr*. 1996;17:328–334
84. Kohen DP, Botts P. Relaxation-imagery (self-hypnosis) in Tourette syndrome: experience with four children. *Am J Clin Hypn*. 1987;29:227–237
85. Lazarus JE, Klein SK. Nonpharmacological treatment of tics in Tourette syndrome adding videotape training to self-hypnosis. *Journal of Developmental & Behavioral Pediatrics*. 2010 Jul 1;31(6):498-504
86. Kohen DP, Mahowald MW, Rosen GM. Sleep-terror disorder in children: the role of self-hypnosis in management. *Am J Clin Hypn*. 1992;34:233–244